Your browser doesn't support javascript.
Evaluation of commercially available immuno-magnetic agglutination in comparison to enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19.
Moeller, Maria E; Fock, Jeppe; Pah, Pearlyn; Veras, Antia De La C; Bade, Melanie; Donolato, Marco; Israelsen, Simone B; Eugen-Olsen, Jesper; Benfield, Thomas; Engsig, Frederik N.
  • Moeller ME; Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre Hospital, Hvidovre, Denmark.
  • Fock J; BluSense Diagnostics ApS, Copenhagen, Denmark.
  • Pah P; BluSense Diagnostics ApS, Copenhagen, Denmark.
  • Veras AC; BluSense Diagnostics ApS, Copenhagen, Denmark.
  • Bade M; BluSense Diagnostics ApS, Copenhagen, Denmark.
  • Donolato M; BluSense Diagnostics ApS, Copenhagen, Denmark.
  • Israelsen SB; Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre Hospital, Hvidovre, Denmark.
  • Eugen-Olsen J; Department of Clinical Research, Copenhagen University Hospital, Amager and Hvidovre Hospital, Hvidovre, Denmark.
  • Benfield T; Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre Hospital, Hvidovre, Denmark.
  • Engsig FN; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
J Med Virol ; 93(5): 3084-3091, 2021 05.
Article in English | MEDLINE | ID: covidwho-1196538
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

INTRODUCTION:

Coronavirus disease 2019 (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Fast, accurate, and simple blood-based assays for quantification of anti-SARS-CoV-2 antibodies are urgently needed to identify infected individuals and keep track of the spread of disease.

METHODS:

The study included 33 plasma samples from 20 individuals with confirmed COVID-19 by real-time reverse-transcriptase polymerase chain reaction and 40 non-COVID-19 plasma samples. Anti-SARS-CoV-2 immunoglobulin M (IgM)/immunoglobulin A (IgA) or immunoglobulin G (IgG) antibodies were detected by a microfluidic quantitative immunomagnetic assay (IMA) (ViroTrack Sero COVID IgM + IgA/IgG Ab, Blusense Diagnostics) and compared to an enzyme-linked immunosorbent assay (ELISA) (EuroImmun Medizinische Labordiagnostika).

RESULTS:

Of the 33 plasma samples from the COVID-19 patients, 28 were positive for IgA/IgM or IgG by IMA and 29 samples were positive by ELISA. Sensitivity for only one sample per patient was 68% for IgA + IgM and 75% IgG by IMA and 80% by ELISA. For samples collected 14 days after symptom onset, the sensitivity of both IMA and ELISA was around 91%. The specificity of the IMA reached 100% compared to 95% for ELISA IgA and 97.5% for ELISA IgG.

CONCLUSION:

IMA for COVID-19 is a rapid simple-to-use point-of-care test with sensitivity and specificity similar to a commercial ELISA.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / Immunomagnetic Separation / Point-of-Care Testing / COVID-19 Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26854

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / Immunomagnetic Separation / Point-of-Care Testing / COVID-19 Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26854